FibroGen, Inc (NASDAQ:FGEN)‘s stock had its “outperform” rating restated by equities researchers at Leerink Swann in a note issued to investors on Tuesday. They presently have a $82.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $52.00. Leerink Swann’s price objective would indicate a potential upside of 145.51% from the company’s previous close.

FGEN has been the subject of a number of other research reports. Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a research note on Friday, July 21st. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, May 8th. Citigroup Inc. reissued a “buy” rating and set a $48.00 target price on shares of FibroGen in a research note on Monday, June 26th. Finally, William Blair reissued an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. FibroGen currently has an average rating of “Buy” and an average price target of $56.86.

FibroGen (FGEN) traded up 50.6955% during mid-day trading on Tuesday, hitting $50.3323. The stock had a trading volume of 4,577,251 shares. The stock’s market cap is $3.52 billion. FibroGen has a one year low of $15.60 and a one year high of $51.45. The firm’s 50-day moving average is $32.84 and its 200 day moving average is $27.51.

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.01. The company had revenue of $29 million for the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. Equities research analysts expect that FibroGen will post ($1.85) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “FibroGen, Inc (FGEN) Earns “Outperform” Rating from Leerink Swann” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/08/fibrogen-inc-fgen-earns-positive-rating-from-leerink-swann.html.

In related news, insider K Peony Yu sold 5,000 shares of FibroGen stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $26.38, for a total value of $131,900.00. Following the transaction, the insider now owns 227,346 shares in the company, valued at approximately $5,997,387.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $26.21, for a total transaction of $1,012,649.56. Following the completion of the transaction, the chief executive officer now owns 3,345,941 shares in the company, valued at approximately $87,697,113.61. The disclosure for this sale can be found here. Insiders sold a total of 409,974 shares of company stock worth $12,647,338 in the last quarter. Insiders own 14.90% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Airain ltd increased its position in FibroGen by 56.6% in the second quarter. Airain ltd now owns 14,971 shares of the biopharmaceutical company’s stock valued at $484,000 after buying an additional 5,409 shares during the last quarter. Prudential Financial Inc. raised its stake in shares of FibroGen by 9.6% in the second quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock valued at $14,496,000 after buying an additional 39,430 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of FibroGen by 589.1% in the second quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 6,327 shares during the period. Legal & General Group Plc raised its stake in shares of FibroGen by 12.2% in the second quarter. Legal & General Group Plc now owns 21,333 shares of the biopharmaceutical company’s stock valued at $684,000 after buying an additional 2,317 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of FibroGen by 19.9% in the second quarter. Bank of New York Mellon Corp now owns 292,636 shares of the biopharmaceutical company’s stock valued at $9,452,000 after buying an additional 48,495 shares during the period. Institutional investors own 43.45% of the company’s stock.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Analyst Recommendations for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.